Blood-Based KRAS Testing Not Sufficient To Detect Mutations In Patients With LGSOC, Study Finds

Medscape (6/24, Evangelou, Subscription Publication) reports a study presented at the European Society for Medical Oncology Gynecological Cancers Congress 2025 found that “blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC).” Utilizing the “Tempus xF panel, which tests 105 cancer-related genes, including KRAS, researchers found that only 32% of patients had detectable ctDNA levels above the 0.25% limit of detection.” The findings “suggest that treatment decisions should continue to rely on traditional tumor tissue analysis rather than liquid biopsies for this rare cancer subtype.”